Liposomal doxorubicin: A review of its use in metastatic breast cancer and potential in non-Hodgkin lymphoma

American Journal of Cancer

Volumn 4, Issue 3, 2005, Pages 193-206

  Dando, Toni M ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTIESTROGEN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOCETAXEL; DOXORUBICIN; DOXORUBICINOL; EPIRUBICIN; FLUORACIL; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; LIPOSOME; METHOTREXATE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PREDNISONE; RITUXIMAB; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINCA ALKALOID; VINCRISTINE;

ALOPECIA; ANEMIA; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEART MUSCLE INJURY; HUMAN; INJECTION SITE REACTION; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PATIENT; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; STOMATITIS; THROMBOCYTOPENIA;

EID: 23744450488     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200504030-00006     Document Type: Review

References (44)

1. Assersohn L, Johnston SRD. Postmenopausal metastatic breast cancer: a review of first-line treatment options. Am J Cancer 2003; 2 (2): 95-109
2. Marty M. Liposomal doxorubicin (Myocet) and conventional anthracyclines: a comparison. Breast 2001; 10 Suppl. 2: 28-33
3. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist 2003; 8 Suppl. 2: 17-24
4. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer 2003 Jun 1; 97 (11): 2869-79
5. Batist G, Barton J, Chaikin P, et al. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin Pharmacother 2002 Dec; 3 (12): 1739-51
6. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000 Apr; 22 (4): 263-302
7. Elan. Myocet: summary of product characteristics [online]. Available from URL: http://www.emea.eu.it [Accessed 2004 Nov 3]
8. Batist G. Improving the therapeutic index when using Myocet in the treatment of metastatic breast cancer. Breast 2001; 10 Suppl. 2: 16-21
9. Swenson CE, Perkins WR, Roberts P, et al. Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate). Breast 2001; 10 Suppl. 2: 1-7
10. Mayer LD, Bally MB, Cullis PR, et al. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 1990; 53: 183-90
11. Swenson CE, Bolcsak LE, Batist G, et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 2003 Mar; 14: 239-46
12. Mross K, Niemann B, Massing U, et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol 2004 Aug; 54: 514-24
13. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001 Mar 1; 19: 1444-54
14. EMEA. Myocet: scientific discussion [online]. Available from URL: http://www.emea.eu.it [Accessed 2005 Feb 14]
15. Roberts P, Janoff AS, Mayhew E. Doxorubicin fluorescence in a human breast carcinoma (MX-1), after treatment with liposome-associated or free doxorubicin [abstract no. 3327]. Proc Am Assoc Cancer Res 2000; 41: 522
16. Hamilton A, Biganzoli L, Coleman R, et al. EORTC 10968: a phase I clinical and nonpharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer. Ann Oncol 2002; 13: 910-8
17. A phase I multicentre clinical and pharmacokinetic study of Myocet™ (liposomal updoxorubicin) in combination with cyclophosphamide in patients with metastatic breast cancer who have normal or abnormal liver biochemistry. Oxford: Zeneus Pharma Ltd, 2005. (Data on file)
18. Iannitti D, Rathore R, Safran H, et al. TLC D-99 can be safely administered to patients with advanced hepatobiliary carcinomas and severe hepatobiliary dysfunction [abstract no. 1214]. Proc Am Soc Clin Oncol 2000 May 20; 19
19. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002 Jan 1; 94: 25-36
20. Chan S, Davidson N, Juozaityte E, et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 2004 Oct; 15 (10): 1527-34
21. Batist G, Harris L, Azarnia N, et al. Improved therapeutic index of TLC D-99 (liposome-encapsulated doxorubicin) compared to free doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin [abstract no. 405]. Proc Am Soc Clin Oncol 2000; 19: 105a
22. Theodoulou M, Campos SM, Batist G, et al. TLC D99 (D, Myocet) and herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis [abstract no. 216]. Proc Am Soc Clin Oncol 2002; 21: 55a
23. Cortes J, Climent M, Lluch A, et al. Updated results of a phase II study (M77035) of Myocet® combined with weekly Herceptin ®and paclitaxel in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (LABC/MBC) [abstract no. 3041]. Breast Cancer Res Treat 2004; 88 Suppl. 1: 125-126.
24. Plus poster presented at the 27th Annual San Antonio Breast Cancer Symposium; 2004 Dec 8-11; San Antonio (TX)
25. Schmid P, Krocker J, Dieing A, et al. Gemcitabine, myocet and docetaxel for primary treatment of breast cancer [abstract no. v269]. Onkologie 2003; 26 Suppl. 5: 22
26. Valero V, Buzdar AU, Theriault RL, et al. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol 1999 May; 17: 1425-34
27. National Cancer Institute. Adult non-Hodgkin's lymphoma (PDQ®): treatment - health professional version [online]. Available from URL: http://www.cancer.gov [Accessed 2004 Sep 29]
28. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002 Jan 24; 346 (4): 235-42
29. Levine AM, Tulpule A, Espina B, et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol 2004 Jul 1; 22 (13): 2662-70
30. Tulpule A, Espina BM, Berman N, et al. A phase I/II trial of liposomal doxorubicin (TLC-D99, myocet) in combination with cyclophosphamide, vincristine, and prednisone (COMP) for newly diagnosed intermediate and high grade non-Hodgkin's lymphoma (NHL) [abstract no. 329]. Eur J Cancer 2001 Oct; 37 Suppl. 6: S91.
31. Plus poster presented at the European Cancer Conference; 2001 Oct 21-25; Lisbon
32. Federico M, Dyer MJS, Caballero MD, et al. The MYOCAN study: a phase II study of cyclophosphamide, oncovin, Myocet., and prednisone plus rituximab (R-COMP) in the treatment of elderly patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) [abstract no. 4586]. Blood 2004 Nov 16; 104 (11 Pt 2): 230b
33. Cancer Care Ontario Guidelines Initiative. Epirubicin, as a single agent or in combination, for metastatic breast cancer: practice guideline report #1-6 (updoxorubicin) date) [online]. Available from URL: http://www.cancercare.on.ca [Accessed 2005 May 12]
34. Barcelon: Zeneus Pharma Ltd, 2005. (Data on file)
35. American Cancer Society. Cancer facts & figures 2005 [online]. Available from URL: http://www.cancer.org [Accessed 2005 Jan 21]
36. National Comprehensive Cancer Network. Clinical practice guidelines in oncology - version 1.2005: breast cancer [online]. Available from URL: http://www.nccn.org [Accessed 2005 Jan 21]
37. Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. Oncologist 2003; 8: 514-20
38. European Society for Medical Oncology. Minimal clinical recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC) [online]. Available from URL: http://www.esmo.org [Accessed 2005 Jan 21]
39. National Cancer Institute. Breast cancer (PDQ®): treatment: health professional version [online]. Available from URL: http://www.cancer.gov [Accessed 2004 Sep 29]
40. Crown J, Dieras V, Kaufmann M, et al. Chemotherapy for metastatic breast cancer: report of a European expert panel. Lancet Oncol 2002 Dec; 3: 719-26
41. Rivera E. Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist 2003; 8 Suppl. 2: 3-9
42. O'Brien MER, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440-9
43. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 (11): 783-92
44. Shapiro CL, Ervin T, Welles L, et al. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. J Clin Oncol 1999 May; 17: 1435-41